Cardiologic prophylaxis for Contrast Induced Nephropathy (CARCIN-trial)

Cardiologic prophylaxis for Contrast Induced Nephropathy (CARCIN-trial) - CarCIN-trial

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

NL-OMON

Registry ID

NL-OMON43732

Enrollment

Registered

2014-12-15

Start date

2015-01-13

Completion date

Unknown

Last updated

2024-06-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Contrast-induced-nephropathy kidney failure

Interventions

None listed

Eligibility

Age

18 Years to 99 Years

Inclusion criteria

Inclusion criteria: Patient is planned for Contrast enhanced CT and/or TAVI-procedure eGFR

Exclusion criteria

Exclusion criteria: M. Kahler / M. Waldenström

Design outcomes

Primary

Measure	Time frame
The level of serum creatinine and eGFR 2-5 days (48-120 hours) after contrast administration compared to pre-contrast baseline serum creatinine.	—

Secondary

Measure	Time frame
• Occurrence of CIN (Contrast Induced Nefropathy, defined as an increase of serum creatinine >25% or 44.2 µmol/l within 2-5 days according to international definitions for AKI. • Level of increase of NT-proBNP in serum • Self-reported level of dyspnoea using the BORG-CR10 scale compared before and after hydration	—

Countries

Netherlands

Outcome results